Clinical Trial Update: Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib [Phase 2]

View source ↗

Summary

This document provides an update on a Phase II trial (Neo-Bio-ADAURA) evaluating mechanisms of resistance to neoadjuvant osimertinib in non-squamous non-small c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: Jair Bar, M.D., Ph.D. | Conditions: Non-squamous NSCLC | Phase 2 | Status: RECRUITING